Nice timing for glitazones

Clifford J. Bailey*, Caroline Day, Andrew J. Krentz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

The National Institute for Clinical Excellence (NICE) recently revised its guidance on the use of thiazolidinediones (TZDs). Days later, the European Agency for the Evaluation of Medicinal Products (EMEA) announced licence changes for TZDs that supersede the NICE guidance. The EMEA has approved TZDs for monotherapy if metformin is contraindicated or not tolerated. This article summarises the latest changes surrounding the use of TZDs in the UK.

Original languageEnglish
Pages (from-to)366-367
Number of pages2
JournalBritish Journal of Diabetes and Vascular Disease
Volume3
Issue number5
DOIs
Publication statusPublished - 1 Sep 2003

Keywords

  • EMEA
  • NICE
  • Pioglitazone
  • Rosiglitazone
  • Thiazolidinediones

Fingerprint

Dive into the research topics of 'Nice timing for glitazones'. Together they form a unique fingerprint.

Cite this